On July 23 and 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee held a closely watched meeting to consider whether seven peptide-related bulk drug substances should be eligible for use in medications prepared by Section 503A compounding pharmacies.
By the end of the two-day meeting, the committee had recommended six peptide groups for inclusion on the 503A Bulks List:
The committee did not recommend adding emideltide, also commonly known as delta sleep-inducing peptide or DSIP. The FDA must still review the committee’s recommendations and make its final determinations.
Still, the votes represent one of the most significant regulatory developments involving compounded peptides in recent years. If the FDA adopts the recommendations, qualified compounding pharmacies could gain a clearer pathway for preparing these peptides for individual patients with valid prescriptions.
What Was the FDA Peptide Meeting About?
The meeting was held by the Pharmacy Compounding Advisory Committee, commonly abbreviated as PCAC.
PCAC is an independent advisory group that provides the FDA with scientific, medical and pharmacy-related recommendations. Its responsibilities include evaluating bulk drug substances nominated for inclusion on the Section 503A Bulks List.
Section 503A of the Federal Food, Drug, and Cosmetic Act establishes conditions under which a licensed pharmacist or physician may prepare a compounded medication for an individual patient.
When a substance does not have an applicable United States Pharmacopeia or National Formulary monograph and is not an ingredient in an FDA-approved drug, it generally must appear on the 503A Bulks List to qualify for use in Section 503A compounding.
The FDA evaluates nominated substances using four primary criteria:
- The substance’s physical and chemical characteristics
- Potential safety considerations associated with compounded use
- Available evidence of effectiveness or lack of effectiveness
- Historical use of the substance in compounded medications
The July meeting gave FDA representatives, committee members, peptide researchers, healthcare professionals, pharmacy representatives and members of the public an opportunity to discuss how these criteria applied to each peptide.
Which Peptides Did the Committee Review?
The committee evaluated seven peptide groups, including both the free-base and acetate forms of each substance.
The FDA focused its scientific review on particular proposed uses:
Recommended Inclusion:
- BPC-157: Ulcerative colitis
- KPV: Wound healing and inflammatory conditions
- TB-500: Wound healing
- MOTS-c: Obesity and osteoporosis
- Epitalon: Insomnia
- Semax: Cerebral ischemia, migraine and trigeminal neuralgia
Did Not Recommend Inclusion:
- Emideltide/DSIP: Opioid withdrawal, chronic insomnia and narcolepsy
The uses considered during the meeting are important because they define the evidence FDA staff reviewed. They do not necessarily represent every use for which these peptides have been researched, prescribed internationally or discussed within regenerative wellness.
How Did the Committee Vote?
The votes were relatively close, reflecting different perspectives on the level of evidence required for inclusion on the compounding list.
- BPC-157, KPV and TB-500 received identical 8–6 recommendations, with one committee member abstaining from each vote.
- MOTS-c received seven votes in favor and five against, with two abstentions. On the second day, the committee also recommended Epitalon and Semax.
- Emideltide was the only peptide that did not receive majority support. Six members voted in favor of its inclusion, seven voted against it and one abstained.
Why Were the Recommendations Significant?
Before the meeting, FDA staff proposed that none of the seven peptide groups be included on the 503A Bulks List.
The committee ultimately reached a different conclusion for six of them.
FDA reviewers emphasized gaps in published human research, questions about chemical identity and manufacturing quality, and the limitations of existing safety and effectiveness data. Many of the peptides have substantial laboratory or animal research behind them, but direct clinical evidence varies considerably from one substance to another.
Committee members supporting inclusion focused on a different practical question: whether patients would be better served by accessing these substances through licensed clinicians and regulated compounding pharmacies instead of unregulated online suppliers.
Peptides are already widely available through websites that label products “for research use only.” These products may be sold without a prescription, clinical evaluation or reliable confirmation of their identity, strength, purity or sterility.
Several committee members argued that a legitimate compounding pathway could bring peptide use into a more structured healthcare environment involving:
- Valid prescriptions
- Licensed healthcare providers
- Qualified compounding pharmacies
- Patient-specific treatment decisions
- Greater supply-chain accountability
- More consistent formulation and quality practices
- Clinical monitoring and follow-up
That access-versus-evidence question became one of the meeting’s central themes.
The committee was not deciding whether the peptides had completed the clinical development required for FDA drug approval. It was deciding whether they could be appropriate ingredients for patient-specific compounded medications.
For six of the seven peptide groups, a majority concluded that inclusion on the 503A Bulks List should be recommended.
What Did the Committee Decide About BPC-157?
BPC-157 was evaluated primarily in connection with ulcerative colitis.
The peptide is a synthetic 15-amino-acid sequence derived from a naturally occurring gastric protein. It has been studied for its potential relationship with gastrointestinal integrity, blood-vessel formation, inflammatory signaling and tissue recovery.
FDA staff raised questions about the limited amount of controlled human research and whether the available evidence sufficiently established safety and effectiveness for compounded use.
The committee nevertheless voted 8–6, with one abstention, to recommend adding BPC-157 free base and BPC-157 acetate to the 503A Bulks List.
The favorable recommendation represents meaningful regulatory progress for one of the most widely discussed peptides in regenerative and recovery-focused medicine.
What Did the Committee Decide About KPV?
KPV was reviewed for wound healing and inflammatory conditions.
KPV is a three-amino-acid fragment derived from the end of alpha-melanocyte-stimulating hormone. Experimental research has connected it with inflammatory signaling, intestinal peptide transport, epithelial-barrier support and antimicrobial activity.
Much of the available evidence comes from laboratory studies, human-derived cells and animal models rather than direct human clinical trials.
The committee voted 8–6, with one abstention, to recommend including KPV free base and KPV acetate on the 503A Bulks List.
If adopted by the FDA, the recommendation could create a clearer pathway for clinicians and researchers interested in KPV’s potential applications involving inflammatory balance, digestive wellness, skin health and tissue recovery.
What Did the Committee Decide About TB-500?
TB-500 was evaluated in connection with wound healing.
The peptide is a synthetic fragment associated with the actin-binding region of thymosin beta-4. It has attracted interest for its potential relationship with cell migration, angiogenesis, connective-tissue remodeling and physical recovery.
Human clinical research has primarily evaluated full-length thymosin beta-4 rather than the shorter TB-500 fragment. This distinction was part of the FDA’s assessment of the available evidence.
The committee voted 8–6, with one abstention, to recommend adding TB-500 free base and TB-500 acetate to the list.
The vote represents an important step toward a more clearly defined regulatory pathway for physician-supervised access to compounded TB-500.
What Did the Committee Decide About MOTS-c?
MOTS-c was evaluated for obesity and osteoporosis.
Unlike many peptides produced from nuclear DNA, MOTS-c is derived from mitochondrial DNA. Researchers are studying its potential role in cellular energy regulation, glucose metabolism, insulin sensitivity, exercise capacity and metabolic adaptation.
The peptide has produced encouraging findings in laboratory and animal research, although direct human treatment studies remain limited.
The committee voted 7–5, with two abstentions, to recommend adding MOTS-c free base and MOTS-c acetate to the 503A Bulks List.
The recommendation could encourage continued research into mitochondrial peptides and their potential relationship with metabolic health, body composition and healthy aging.
What Did the Committee Decide About Epitalon?
Epitalon was evaluated in connection with insomnia.
Epitalon is a synthetic four-amino-acid peptide modeled after epithalamin-related research. It is commonly discussed in connection with sleep, circadian rhythms, cellular aging and telomere biology.
The available evidence includes laboratory, animal and international research, but FDA reviewers identified limitations in the quality and applicability of the data.
The committee voted 7–4 to recommend including Epitalon free base and Epitalon acetate on the 503A Bulks List.
The recommendation marks a positive regulatory development for a peptide that has long attracted interest within sleep, longevity and healthy-aging research.
What Did the Committee Decide About Semax?
Semax was evaluated for cerebral ischemia, migraine and trigeminal neuralgia.
It is a synthetic peptide derived from a fragment of adrenocorticotropic hormone and has been studied for its potential effects on neurological signaling, neurotrophic factors, oxidative stress and cognitive function.
Semax has a longer history of clinical use and research in Russia and several Eastern European countries than it does in the United States. Committee members discussed how that international experience should be weighed alongside the standards and evidence available to U.S. regulators.
The committee voted 8–5, with one abstention, to recommend including Semax free base and Semax acetate on the 503A Bulks List.
The favorable vote could support a more structured U.S. pathway for continued clinical evaluation and physician-supervised compounded use.
Why Was Emideltide (DSIP) Not Recommended?
Emideltide, also known as delta sleep-inducing peptide or DSIP, was evaluated for opioid withdrawal, chronic insomnia and narcolepsy.
The committee reviewed its chemical characteristics, historical use and available scientific literature. Members ultimately expressed less confidence in the evidence supporting the proposed applications.
Six members voted to recommend inclusion, seven voted against it and one abstained.
Although the committee did not recommend emideltide during this meeting, the narrow vote shows that interest in the peptide remains. Future nominations or regulatory reviews could potentially consider additional research, improved characterization or new clinical evidence.
Did the FDA Approve These Peptides?
The July 2026 meeting was not an FDA drug-approval proceeding.
As of August 2026, BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax have not received formal FDA approval.
The committee recommended that they be included on the 503A Bulks List, which is a separate regulatory pathway governing ingredients used in certain compounded medications.
FDA approval generally requires a drug sponsor to complete clinical trials and submit evidence demonstrating that a specific finished medication is safe and effective for a particular use. The FDA also evaluates the medication’s manufacturing process, labeling, dosage and formulation.
Compounded medications are prepared for individual patients based on prescriptions and do not undergo that same premarket approval process.
What Happens After the Committee Vote?
The FDA will now consider the committee’s recommendations alongside its own scientific reviews, public comments and any additional information available to the agency.
The FDA is not legally required to follow PCAC’s recommendations, although advisory committee votes can carry significant influence.
For a substance to be formally added to the 503A Bulks List, the FDA must complete the applicable regulatory process. Until that happens, the committee’s vote alone does not authorize pharmacies to begin compounding the substances under Section 503A.
Possible next steps may include:
- FDA review of the committee’s recommendations
- Additional analysis of chemical identity and quality standards
- Consideration of limitations involving formulation or administration
- Publication of a proposed regulatory action
- An additional public-comment period
- A final FDA determination
What Does the Meeting Mean for Patients?
The immediate regulatory status of these peptides has not changed, but the meeting could shape how patients access them in the future.
If the FDA adopts the recommendations, the clearest potential benefit would be movement away from anonymous “research use only” sellers and toward a healthcare model centered on licensed providers and qualified pharmacies.
That could give patients greater confidence that treatment decisions are based on:
- A review of medical history
- Individual treatment goals
- Appropriate formulation and dosing
- Pharmacy quality standards
- Ongoing clinical monitoring
- Clear communication about the current evidence
- A valid provider-patient relationship
The vote also brings greater visibility to the need for continued peptide research. Inclusion on a compounding list does not replace clinical trials, but increased regulatory clarity may encourage better collection of clinical data and a more informed understanding of how these substances perform in real-world care.
What the July 2026 Meeting Means for the Future of Peptide Therapy
The meeting demonstrated that compounded peptides are no longer a fringe regulatory issue.
Patients are already seeking these therapies, clinicians are already discussing them and researchers continue to investigate their biological mechanisms. The central question is increasingly becoming how peptide therapy can develop within a more responsible and transparent healthcare framework.
The committee’s decision to recommend six of the seven peptide groups suggests growing recognition that carefully regulated access may offer a more practical path than leaving patients to navigate an unregulated online market.
It also reinforces the importance of separating legitimate clinical care from exaggerated marketing.
The recommendations do not prove that every proposed peptide benefit is effective. They do, however, move the conversation toward licensed medical supervision, accountable pharmacy sourcing and clearer federal standards.
For BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax, the July 2026 votes represent meaningful progress—but not the end of the regulatory process.
RegenMD Wellness will continue monitoring FDA activity involving these substances and updating patients as final decisions and new research become available.
This article is provided for general educational purposes and does not constitute medical advice. Research discussed may include laboratory, animal, and human studies. Patients should always consult a licensed clinician when considering peptide therapy.
Sources
- U.S. Food and Drug Administration. “July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee.” July 2026.
- U.S. Food and Drug Administration. “FDA Briefing Document Introduction: July 23–24, 2026 Pharmacy Compounding Advisory Committee Meeting.” July 2026.
- U.S. Food and Drug Administration. “Voting Questions: July 23–24, 2026 Pharmacy Compounding Advisory Committee Meeting.” July 2026.
- U.S. Food and Drug Administration. “July 23, 2026 Pharmacy Compounding Advisory Committee Presentations.” July 2026.
- U.S. Food and Drug Administration. “July 24, 2026 Pharmacy Compounding Advisory Committee Presentations.” July 2026.
- Reuters. “FDA Advisers Recommend Relaxing U.S. Rules on Compounding Peptides.” July 24, 2026.
- Reuters. “FDA Advisory Panel Recommends Peptide Semax Be Added to Pharmacy Compounding List.” July 24, 2026.
- Reuters. “FDA Panel Votes to Exclude Peptide Emideltide From Pharmacy Compounding List.” July 24, 2026.
